Our Science

OUR PIPELINE

Alnylam has led the translation of RNAi (RNA interference) into an innovative new class of medicines which silence the genes that cause disease or that contribute to disease. Our pioneering science and pipeline of investigational RNAi therapeutics are focused on addressing the needs of patients who have limited or inadequate treatment options for diseases that currently fall under 4 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.

Our RNAi therapeutics platform and drug development approach aims to generate 2-4 new investigational new drug (IND) applications each year.

Learn more about our clinical trials here ›